Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | PAM | P19021 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3884868 | 1.00 | RAB9A (0.47) | RAB9AKDM4EALDH1A1PRMT1MAOB | |
| (Z)-1,2-Diphenylethene SCHEMBL11896257 | 0.90 | ALDH1A1 (0.44) | RAB9AKDM4EALDH1A1MAOBMEN1 | |
| SCHEMBL2770961 | 0.89 | KDM4E (0.55) | RAB9AKDM4EALDH1A1PRMT1MAOB | |
| SCHEMBL2770965 | 0.89 | KDM4E (0.55) | RAB9AKDM4EALDH1A1PRMT1MAOB | |
| SCHEMBL11200701 | 0.83 | ADRB2 (0.42) | RAB9AKDM4EPRMT1MAOBIDO1 | |
| SCHEMBL4356479 | 0.82 | RAB9A (0.49) | RAB9AKDM4EALDH1A1PRMT1MAOB | |
| SCHEMBL4356484 | 0.82 | RAB9A (0.49) | RAB9AKDM4EALDH1A1PRMT1MAOB | |
| SCHEMBL11597360 | 0.81 | PRMT1 (0.55) | RAB9AKDM4EALDH1A1PRMT1MAOB | |
| SCHEMBL14275030 | 0.81 | KDM4E (0.52) | RAB9AKDM4EALDH1A1PRMT1MAOB | |
| Styrene SCHEMBL608141 | 0.81 | ALDH1A1 (0.64) | RAB9AKDM4EALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193391-B2 | Process for preparation of 3-(2-hydroxy-5-substituted phenyl)-N-alkyl-3-phenylpropylamines | LEK PHARMACEUTICALS, D.D. (SI) | 2012-06-05 | — | — | US | disclosed |
| US-7550500-B2 | Bicyclic and tricyclic amines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| EP-2044001-A1 | PROCESS FOR PREPARATION OF 3-(2-HYDROXY-5-SUBSTITUTED PHENYL)-N-ALKYL-3-PHENYLPROPYLAMINES | Lek Pharmaceuticals D.D. (SI) | 2009-04-08 | — | — | EP | disclosed |
| WO-2007147547-A1 | PROCESS FOR PREPARATION OF 3-(2-HYDROXY-5-SUBSTITUTED PHENYL)-N-ALKYL-3-PHENYLPROPYLAMINES | LEK PHARMACEUTICALS D.D. (SI) | 2007-12-27 | — | — | WO | disclosed |
| US-20060014964-A1 | Bicyclic and tricyclic amines as modulators of chemokine receptor activity | DUNCIA JOHN V | 2006-01-19 | — | — | US | disclosed |
| US-6960666-B2 | Bicyclic and tricyclic amines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| US-20040209876-A1 | Bicyclic and tricyclic amines as modulators of chemokine receptor activity | DUNCIA JOHN V (US) | 2004-10-21 | — | — | US | disclosed |
| US-6784200-B2 | SUCH AS N-3-(CIS-2,3,3A,4,9,9A-HEXAHYDRO-1H-BENZ(F)ISOINDOL-2-YL)-N-PROP-1-YL-N'-3 -ACETYLPHENYLUREA FOR PREVENTION OF INFLAMMATORY DISEASES (ASTHMA AND ALLERGIES) | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-08-31 | — | — | US | disclosed |
| US-20040006084-A1 | Bicyclic and tricyclic amines as modulators of chemokine receptor activity | DUNCIA JOHN V (US) | 2004-01-08 | — | — | US | disclosed |
| EP-0740658-B1 | N-SUBSTITUTED AZABICYCLOHEPTANE DERIVATIVES USED, FOR EXAMPLE, AS NEUROLEPTICS | ABBOTT GMBH & CO KG (DE) | 2003-07-02 | — | — | EP | disclosed |
| US-5521209-A | N-substituted azabicyclo[3.2.0]heptane derivatives as neuroleptics, the preparation and use thereof | BASF AKTIENGESELLSCHAFT (DE) | 1996-05-28 | — | — | US | disclosed |
| US-5475105-A | N-substituted azabicycloheptane derivatives | BASF AKTIENGESELLSCHAFT (DE) | 1995-12-12 | — | — | US | disclosed |
| US-5473080-A | Substituted azabicycloheptane derivatives, their preparation and use | BASF AKTIENGESELLSCHAFT (DE) | 1995-12-05 | — | — | US | disclosed |
| WO-1995015312-A1 | N-SUBSTITUTED AZABICYCLOHEPTANE DERIVATIVES USED, FOR EXAMPLE, AS NEUROLEPTICS | BASF AKTIENGESELLSCHAFT (DE) | 1995-06-08 | — | — | WO | disclosed |
| EP-0647231-A1 | N-SUBSTITUTED 3-AZABICYCLO 3.2.0]HEPTANE DERIVATES USEFUL AS NEUROLEPTIC AGENTS, ETC. | BASF AG (DE) | 1995-04-12 | — | — | EP | disclosed |
| EP-0646110-A1 | N-SUBSTITUED 3-AZABICYCLO 3.2.0]HEPTANE DERIVATIVES USEFUL AS NEUROLEPTIC AGENTS ETC. | BASF AG (DE) | 1995-04-05 | — | — | EP | disclosed |
| EP-0646113-A1 | SUBSTITUED 3-AZABICYCLO 3.2.0]HEPTANE DERIVATES USEFUL AS INTERMEDIATE PRODUCTS. | BASF AG (DE) | 1995-04-05 | — | — | EP | disclosed |
| WO-1994000431-A1 | N-SUBSTITUED 3-AZABICYCLO[3.2.0]HEPTANE DERIVATIVES USEFUL AS NEUROLEPTIC AGENTS ETC. | BASF AKTIENGESELLSCHAFT (DE) | 1994-01-06 | — | — | WO | disclosed |
| WO-1994000458-A1 | N-SUBSTITUTED 3-AZABICYCLO[3.2.0]HEPTANE DERIVATES USEFUL AS NEUROLEPTIC AGENTS, ETC. | BASF AKTIENGESELLSCHAFT (DE) | 1994-01-06 | — | — | WO | disclosed |
| WO-1994000445-A1 | SUBSTITUED 3-AZABICYCLO[3.2.0]HEPTANE DERIVATES USEFUL AS INTERMEDIATE PRODUCTS | BASF AKTIENGESELLSCHAFT (DE) | 1994-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209876-A1 | Bicyclic and tricyclic amines as modulators of chemokine receptor activity | CCR1, CCR3, CCR10 | RAB9A 1544/4885KDM4E 4658/4885ALDH1A1 964/4885 |
| US-20040006084-A1 | Bicyclic and tricyclic amines as modulators of chemokine receptor activity | CCR1, CCR3, CCR10 | RAB9A 1544/4885KDM4E 4658/4885ALDH1A1 964/4885 |
| US-20060014964-A1 | Bicyclic and tricyclic amines as modulators of chemokine receptor activity | CCR3, CCR1, NR1I3 | RAB9A 1448/4885KDM4E 4209/4885ALDH1A1 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.